Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ianalumab in Warm Autoimmune Hemolytic Anemia (wAIHA)
NCT05648968Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Dec 2022
- Primary completion
- Feb 2026
- Countries
- 16
01
Overview
A Phase 3 trial of ianalumab in warm autoimmune hemolytic anemia (wAIHA), sponsored by Novartis. Started Dec 2022; status: active, not recruiting.
02
Drugs
ianalumab
03
Conditions
warm autoimmune hemolytic anemia (wAIHA)
Beyond the preview
Go deeper on NCT05648968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05648968.